August 1, 2012 — Bayer AG has paid $402.6 million to settle almost 1,900 Yasmin lawsuits. Most of the lawsuits allege that Bayer failed to adequately warn about the risk of blood clots, which can lead to heart attacks, strokes, pulmonary embolisms, severe venous damage, and death. Each blood clot case has been settled for an average of $212,000.
Bayer is also in the process of settling Yaz lawsuits. The company has set aside $610.5 million to settle those cases. In 2010 and 2011, the company set aside about $250 million. The company may be forced to pay $1.2 billion to settle all of the lawsuits.
The information was published in a stockholders newsletter, which also said that the company was raising revenue and earnings forecasts. Revenue is expected to increase 4-5% to approximately $50 billion dollars.
The newsletter also mentioned that the company is facing approximately 12,000 Yasmin lawsuits. Of these, approximately 6,000 lawsuits involve venous blood clots, which have caused injuries such as Deep Vein Thrombosis (DVT) and pulmonary embolisms. Bayer is actively settling these types of cases.
Bayer has refused to settle lawsuits from women who allege Yasmin caused arterial blood clots. These clots can cause stroke, heart attack, severe brain damage, and death. Some of the most serious Yasmin lawsuits involve arterial blood clots. Bayer is also refusing to settle lawsuits from women who suffered gallbladder injuries or gallstones after taking Yasmin.